Yale’s Department of Psychiatry Chair to Join Clearmind Medicine
Dr. John H. Krystal, world-leading expert in alcoholism and depression, will serve on scientific advisory board
VANCOUVER, June 21, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the “Company“), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced the appointment to its Scientific Advisory Board of John Krystal, Chair of the Psychiatry Department at Yale University’s School of Medicine.
A leading expert on alcoholism, post-traumatic stress disorder, schizophrenia, and depression, Dr. Krystal’s work links psychopharmacology, neuroimaging, molecular genetics, and computational neuroscience to study the neurobiology and treatment of these disorders. He is best known for leading the discovery of the rapid antidepressant effects of ketamine.
“We are truly honored to add Dr. Krystal, one of the world’s most recognized experts in alcoholism, to our Scientific Advisory Board,” said Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer. “Clearmind has emphasized collaboration with scientists and clinicians at the very best academic, medical and research institutions in the world, helping us bring innovative expertise to bear on some of the most pressing global health needs.”
Dr. Krystal is a Professor of Translational Research; Psychiatry, Neuroscience, and Psychology; he chairs the Department of Psychiatry at Yale University; and he is Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital. He is a graduate of the University of Chicago and the Yale University School of Medicine
Among many other positions he holds or has held, Dr. Krystal is the Director of the NIAAA Center for the Translational Neuroscience of Alcoholism and the Clinical Neuroscience Division of the VA National Center for PTSD, co-director of the Neuroscience Forum of the U.S. National Academies of Sciences, Engineering, and Medicine; and editor of Biological Psychiatry (IF=12.1). He is a member of the U.S. National Academy of Medicine and a Fellow of the American Association for the Advancement of Science.
“We believe that the scientists on our Scientific Advisory Board, working closely with us to challenge, validate and guide our scientific agenda for developing breakthrough therapies that improve human mental-health at scale, increase access to care, reduce suffering and improve health outcomes around the world,” said Zuloff-Shani.
About Clearmind Inc. (CSE: CMND), (OTC: CMNDF), (FSE: CWY0)
Clearmind is a new biotech company focused on the discovery and development of safe and novel psychedelic-derived therapeutics to treat alcohol use disorder and other pressing health challenges.
The Israeli Canadian company holds several patents for the non-hallucinogenic compound MEAI (5-methoxy-2-aminoindane, a novel psychoactive substance). The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Clearmind has established a research collaboration with the Hebrew University of Jerusalem and Bar Ilan University. The partnerships aim to expand its R&D capabilities and discover new candidate treatments for other mental health issues.
For further information, please contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.